...investors Kurma Partners, Idinvest Partners, Stiftelsen Industrifonden and Brohuvudet also participated. OxThera AB , Uppsala, Sweden
Alicia Parker
OxThera AB...
...Flerie Invest. Also participating were existing investors Kurma Partners, Idinvest Partners, Stiftelsen Industrifonden and Brohuvudet. OxThera... ...short bowel syndrome (SBS). It is a capsule formulation of lyophilized live Oxalobacter formigenes .
Chris Lieu
Oxabact
OxThera AB...
...The European Commission granted Orphan Drug designation to Oxabact from OxThera to treat short bowel syndrome... ...U.S. to treat primary hyperoxaluria, for which the compound is in a Phase II trial. OxThera AB...
OxThera AB , Uppsala, Sweden Business: Endocrine/Metabolic Date completed: 4/16/14 Type: Venture financing Raised: SEK70 million ($10.7 million) Investors: Kurma Partners; Idinvest Partners; Mayo Clinic ; existing investors
WIR Staff...
...investors Kurma Partners, Idinvest Partners, Stiftelsen Industrifonden and Brohuvudet also participated. OxThera AB , Uppsala, Sweden
Alicia Parker
OxThera AB...
...Flerie Invest. Also participating were existing investors Kurma Partners, Idinvest Partners, Stiftelsen Industrifonden and Brohuvudet. OxThera... ...short bowel syndrome (SBS). It is a capsule formulation of lyophilized live Oxalobacter formigenes .
Chris Lieu
Oxabact
OxThera AB...
...The European Commission granted Orphan Drug designation to Oxabact from OxThera to treat short bowel syndrome... ...U.S. to treat primary hyperoxaluria, for which the compound is in a Phase II trial. OxThera AB...
OxThera AB , Uppsala, Sweden Business: Endocrine/Metabolic Date completed: 4/16/14 Type: Venture financing Raised: SEK70 million ($10.7 million) Investors: Kurma Partners; Idinvest Partners; Mayo Clinic ; existing investors
WIR Staff...